Hemophilia Management


Expert Interview

Stay Connected

Join the conversation

Hemophilia Quick Facts

Aging and Comorbidities Quick Facts

  • The hemophilia population is aging

    • Average life expectancy now exceeds 70 years, compared with approximately 76 years for males in the general population
    • 13% of current patients are aged 45-64 years
    • 3% of current patients are aged > 65 years
  • Both hypertension and chronic kidney disease are more common in men with hemophilia than in the general population
  • Hemophilia provides some protection from cardiovascular disease (CVD)

    • However, men with hemophilia remain susceptible to CVD, including myocardial infarction and ischemic stroke
  • Treatment of CVD with anticoagulant and antiplatelet therapies is challenging in patients with hemophilia

Centers for Disease Control and Prevention. Report on the Universal Data Collection Program, 2005-2009, January 2014:1-26. 2. Centers for Disease Control and Prevention. Hemophilia.


Q: What best describes your primary role?

Q: Approximately how many patients with hemophilia are being managed in your organization or practice setting?

Q: Which of the following aspects of hemophilia care has the greatest impact on total costs?

Advisory Board

Marion Koerper, MD Professor Emerita on Recall
Department of Pediatric Hematology
School of Medicine University of California, San Francisco
(UCSF) School of Medicine
Medical Advisor
National Hemophilia Foundation

Jennifer Maahs, RN, PNP, MSN
Nurse Practitioner
Indiana Hemophilia and Thrombosis Center

Diane J. Nugent, MD Chair, Hematology
Medical Director, Hematology and Blood and Donor Services
Division Chief, Hematology
Children’s Hospital of Orange County

Vanita K. Pindolia, PharmD, BCPS
Vice President, Ambulatory Clinical Pharmacy Programs_PCM
Henry Ford Health System/Health Alliance Plan of Michigan

Celynda G. Tadlock, PharmD, MBA
Vice President Pharmacy Business Development, Aetna
President, Coventry Prescription Management Serivces, Inc.